Status and phase
Conditions
Treatments
About
This study aims to find out:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Histologically confirmed colorectal, pancreatic, gastric adenocarcinoma, primary liver cancer or metastatic liver disease, or cholangiocarcinoma that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.
Malignancies should possess with ≥10% expression of CDH17 confirmed by immunohistochemistry except for CRC patients.
Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.
Life expectancy > 3 months.
Measurable disease as defined by RECIST 1.1 criteria
Blood coagulation parameters:
Patients must have adequate venous peripheral access for apheresis.
Satisfactory organ and bone marrow function as defined by:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
68 participants in 5 patient groups
Loading...
Central trial contact
Dennis Wong, M.D
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal